Publisher: BizWire Express

Cellworks CBM Clinical Study Identifies Novel Biomarkers for ATRA Benefit and Failure in AML Patients

Published by BizWire Express
In the Media Icon

Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from a Cellworks Clinical Trial, in which the Cellworks Computational Omics Biology Model (CBM) accurately predicted that All-Trans Retinoic Acid (ATRA) combined with cytarabine, etoposide, idarubicin (ATRA-CEI) benefits a subset of non-APL (Acute Promyelocytic… Read More

Intelligent.com Announces Best Colleges In Tennessee for 2021

Published by BizWire Express
In the Media Icon

Intelligent.com, a trusted resource for online degree rankings and higher education planning, has announced the Top 41 Colleges In Tennessee for 2021. The comprehensive research guide is based on an assessment of 184 accredited colleges and universities in the nation. Each institution is evaluated based on curriculum quality, graduation rate, reputation, and post-graduate employment.  … Read More

Veru Expands Oncology Drug Pipeline; Exclusively Licenses Phase 3 Clinical Stage Targeted Therapy for Endocrine Resistant Metastatic Breast Cancer

Published by BizWire Express
In the Media Icon

Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer, today announced that it has exclusively licensed worldwide rights to enobosarm, a late-stage oral novel androgen receptor (AR) targeting agent for the treatment of endocrine resistant ER+ HER2- metastatic breast cancer.… Read More

Cellworks Personalized Biosimulation Clinical Trial Predicted ATO and ATRA Therapy Response in APL Patients with 93% Accuracy

Published by BizWire Express
In the Media Icon

Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-021-01 clinical trial, which found that the Cellworks Omics Biology Model (CBM) predicted response to Arsenic Trioxide (ATO) and All-trans-retinoic Acid (ATRA) in Acute Promyelocytic Leukemia (APL) patients harboring PML-RARA fusions with… Read More

VERU-111 Suppresses Key Cytokines Responsible for Severe Acute Respiratory Distress Syndrome in COVID-19

Published by BizWire Express
In the Media Icon

Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that it has confirmed in an in vitro study that VERU-111 has anti-inflammatory action against the key cytokines involved in the cytokine storm triggered by the SARS-CoV-2 infection.   August… Read More

Accumen Develops New Channels for Critical COVID-19 Supplies and Recovery Resources for Hospitals and Health Systems

Published by BizWire Express
In the Media Icon

Accumen Inc. is helping healthcare get better, faster. Today the company announced the launch of its COVID-19 Resource Center, which provides practical tools for hospital laboratories, supply chain, blood management, and imaging departments supporting patient care during this pandemic.